https://doi.org/10.4081/ahr.2025.30

Efficacy of trigger point injection for non-malignant persistent musculoskeletal pain: a narrative review

Vol. 2 (2025)
Published: January 28, 2025
Trigger point injection , Musculoskeletal pain
Abstract Views: 27
PDF: 76
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Alkisti Giannaki
alkisti.giannaki@gmail.com
https://orcid.org/0009-0006-8236-6015
University College London, United Kingdom.
Martina Rekatsina
University College London, National Kapodistrian University of Athens, United Kingdom.
Mohamed Hassouna
https://orcid.org/0000-0002-6776-2777
University College London, United Kingdom.
Roman Cregg
University College London, United Kingdom.

Myofascial pain is a commonly occurring reason for pain complaints and can affect patients' daily activities, work commitments and well-being. Several non-invasive approaches practised for myofascial trigger point relief are stretching, massage therapy, ischemic compression, and heat- therapy. Invasive treatment for trigger points commonly refers to the injection of fluid directly into the trigger points using a variety of substances, such as sterile water, saline, local anaesthetics, long-acting corticosteroids, or botulinum toxin. This review evaluates the efficacy of trigger point injections (TrPI) for patients with myofascial pain syndrome compared with non-invasive management options through published studies. In accordance with SANRA guidelines, 35 studies that focused on comparing TrPI and other therapeutic interventions managing myofascial pain syndrome, were included. Results indicate that a combination of TrPI, ultrasound therapy and myofascial stretches was found to be more effective than a stand-alone trigger point intervention. Tropisetron showed a 50% decrease in pain, botulinum toxin type A (BTX-A), and lidocaine injection also demonstrated improvement, although short-term, of up to 4 weeks. Physiotherapy in conjunction with BTX-A increased the efficacy of TrPI. Ultimately, both TrPI and ESWT demonstrated comparable results in managing myofascial pain syndrome. A clear limitation was a lack of objective clinical imaging testing while identifying trigger points or tender points. Current practice in treating myofascial pain syndrome remains empirical without established clinical standards. Although, TrPI have demonstrated its value in treating myofascial pain syndrome, future research is warranted addressing its effectiveness within a multidisciplinary approach instead of a stand-alone treatment. Pain perception, culture and genetics should also be taken into consideration in future studies as other risk factors.

Altmetrics

Downloads

Download data is not yet available.
1. Borg-Stein J, Simons DG. Focused review: myofascial pain. Arch Phys Med Rehabil 2002;83:S40-7, S8-9.
2. Salaffi F, De Angelis R, Stancati A, et al. Health-related quality of life in multiple musculoskeletal conditions: a cross-sectional population based epidemiological study. II. The MAPPING study. Clin Exp Rheumatol 2005;23:829-39.
3. National Institute for Health and Care Excellence. Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain. NICE guideline [NG193]. 2022. Available from: https://www.nice.org.uk/guidance/ng193/chapter/Context
4. Gay C, Chabaud A, Guilley E, Coudeyre E. Educating patients about the benefits of physical activity and exercise for their hip and knee osteoarthritis. Systematic literature review. Ann Phys Rehabil Med 2016;59:174-83.
5. Finnerup NB. Nonnarcotic methods of pain management. N Engl J Med 2019;380:2440-8.
6. Eloqayli H. Subcutaneous accessory pain system (SAPS): A novel pain pathway for myofascial trigger points. Med Hypotheses 2018;111:55-7.
7. Celik D, Mutlu EK. Clinical implication of latent myofascial trigger point. Curr Pain Headache Rep 2013;17:353.
8. Gerwin RD. Diagnosis of myofascial pain syndrome. Phys Med Rehabil Clin N Am 2014;25:341-55.
9. Shah JP, Thaker N, Heimur J, et al. Myofascial trigger points then and now: a historical and scientific perspective. PM R 2015;7:746-61.
10. Shah JP, Danoff JV, Desai MJ, et al. Biochemicals associated with pain and inflammation are elevated in sites near to and remote from active myofascial trigger points. Arch Phys Med Rehabil 2008;89:16-23.
11. Bennett R. Fibromyalgia: present to future. Curr Rheumatol Rep 2005;7:371-6.
12. Desmeules JA, Cedraschi C, Rapiti E, et al. Neurophysiologic evidence for a central sensitization in patients with fibromyalgia. Arthritis Rheum 2003;48:1420-9.
13. Staud R, Nagel S, Robinson ME, Price DD. Enhanced central pain processing of fibromyalgia patients is maintained by muscle afferent input: a randomized, double-blind, placebo-controlled study. Pain 2009;145:96-104.
14. Sikdar S, Shah JP, Gebreab T, et al. Novel applications of ultrasound technology to visualize and characterize myofascial trigger points and surrounding soft tissue. Arch Phys Med Rehabil 2009;90:1829-38.
15. Salavati M, Akhbari B, Ebrahimi Takamjani I, et al. Reliability of the upper trapezius muscle and fascia thickness and strain ratio measures by ultrasonography and sonoelastography in participants with myofascial pain syndrome. J Chiropr Med 2017;16:316-23.
16. Gerwin RD. Classification, epidemiology, and natural history of myofascial pain syndrome. Curr Pain Headache Rep 2001;5:412-20.
17. Li L, Stoop R, Clijsen R, et al. Criteria used for the diagnosis of myofascial trigger points in clinical trials on physical therapy: updated systematic review. Clin J Pain 2020;36:955-67.
18. Montenegro ML, Braz CA, Rosa-e-Silva JC, et al. Anaesthetic injection versus ischemic compression for the pain relief of abdominal wall trigger points in women with chronic pelvic pain. BMC Anesthesiol 2015;15:175.
19. Kong LJ, Zhan HS, Cheng YW, et al. Massage therapy for neck and shoulder pain: a systematic review and meta-analysis. Evid Based Complement Alternat Med 2013;2013:613279.
20. Lavelle ED, Lavelle W, Smith HS. Myofascial trigger points. Anesthesiol Clin 2007;25:841-51.
21. Criscuolo CM. Interventional approaches to the management of myofascial pain syndrome. Curr Pain Headache Rep 2001;5:407-11.
22. Borg-Stein J, Iaccarino MA. Myofascial pain syndrome treatments. Phys Med Rehabil Clin N Am 2014;25:357-74.
23. Chen J, Li W, Huang Y, et al. Needling on trigger point promotes muscle regeneration after bupivacaine injection induced injury. Neurosci Lett 2020;739:135436.
24. Saxena A, Chansoria M, Tomar G, Kumar A. Myofascial pain syndrome: an overview. J Pain Palliat Care Pharmacother 2015;29:16-21.
25. Ozkan F, Cakir Ozkan N, Erkorkmaz U. Trigger point injection therapy in the management of myofascial temporomandibular pain. Agri 2011;23:119-25.
26. Gupta P, Singh V, Sethi S, Kumar A. A comparative study of trigger point therapy with local anaesthetic (0.5 % bupivacaine) versus combined trigger point injection therapy and levosulpiride in the management of myofascial pain syndrome in the orofacial region. J Maxillofac Oral Surg 2016;15:376-83.
27. Avrahami D, Hammond A, Higgins C, Vernon H. A randomized, placebo-controlled double-blinded comparative clinical study of five over-the-counter non-pharmacological topical analgesics for myofascial pain: single session findings. Chiropr Man Therap 2012;20:7.
28. Mense S. Neurobiological basis for the use of botulinum toxin in pain therapy. J Neurol 2004;251:I1-7.
29. Wheeler A, Smith HS. Botulinum toxins: mechanisms of action, antinociception and clinical applications. Toxicology 2013;306:124-46.
30. Sorensen J, Bengtsson A, Backman E, et al. Pain analysis in patients with fibromyalgia. Effects of intravenous morphine, lidocaine, and ketamine. Scand J Rheumatol 1995;24:360-5.
31. Graven-Nielsen T, Kendall SA, Henriksson KG, et al. Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. Pain 2000;85:483-91.
32. Lugo LH, Garcia HI, Rogers HL, Plata JA. Treatment of myofascial pain syndrome with lidocaine injection and physical therapy, alone or in combination: a single blind, randomized, controlled clinical trial. BMC Musculoskelet Disord 2016;17:101.
33. Scott NA, Guo B, Barton PM, Gerwin RD. Trigger point injections for chronic non-malignant musculoskeletal pain: a systematic review. Pain Med 2009;10:54-69.
34. Glasziou P, Vandenbroucke JP, Chalmers I. Assessing the quality of research. BMJ 2004;328:39-41.
35. Cook DJ, Mulrow CD, Haynes RB. Systematic reviews: synthesis of best evidence for clinical decisions. Ann Intern Med 1997;126:376-80.
36. Hariton E, Locascio JJ. Randomised controlled trials - the gold standard for effectiveness research: Study design: randomised controlled trials. BJOG 2018;125:1716.
37. Ettlin T. Trigger point injection treatment with the 5-HT3 receptor antagonist tropisetron in patients with late whiplash-associated disorder. First results of a multiple case study. Scand J Rheumatol Suppl 2004;119:49-50.
38. Muller W, Fiebich BL, Stratz T. [5-HT3 receptor antagonist als analgetics in rheumatic diseases].[Article in German].Z Rheumatol 2006;65:546, 8-52.
39. Fakhfouri G, Rahimian R, Dyhrfjeld-Johnsen J, et al. 5-HT(3) receptor antagonists in neurologic and neuropsychiatric disorders: the iceberg still lies beneath the surface. Pharmacol Rev 2019;71:383-412.
40. Stratz T, Varga B, Muller W. Treatment of tendopathies with tropisetron. Rheumatol Int 2002;22:219-21.
41. Esenyel M, Caglar N, Aldemir T. Treatment of myofascial pain. Am J Phys Med Rehabil. 2000;79:48-52.
42. Rezasoltani Z, Ehyaie H, Mofrad RK, et al. Granisetron vs. lidocaine injection to trigger points in the management of myofascial pain syndrome: a double-blind randomized clinical trial. Scand J Pain 2021;21:707-15.
43. Kamanli A, Kaya A, Ardicoglu O, et al. Comparison of lidocaine injection, botulinum toxin injection, and dry needling to trigger points in myofascial pain syndrome. Rheumatol Int 2005;25:604-11.
44. Ferrante FM, Bearn L, Rothrock R, King L. Evidence against trigger point injection technique for the treatment of cervicothoracic myofascial pain with botulinum toxin type A. Anesthesiology 2005;103:377-83.
45. Borodic GE, Pearce LB, Smith K, Joseph M. Botulinum a toxin for spasmodic torticollis: multiple vs single injection points per muscle. Head Neck 1992;14:33-7.
46. Wheeler AH, Goolkasian P, Gretz SS. A randomized, double-blind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome. Spine (Phila Pa 1976) 1998;23:1662-6; discussion 7.
47. Gobel H, Heinze A, Heinze-Kuhn K, Austermann K. Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndromes. Pain 2001;91:195-9.
48. Porta M. A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm. Pain 2000;85:101-5.
49. Ji HM, Kim HJ, Han SJ. Extracorporeal shock wave therapy in myofascial pain syndrome of upper trapezius. Ann Rehabil Med 2012;36:675-80.
50. Eftekharsadat B, Fasaie N, Golalizadeh D, et al. Comparison of efficacy of corticosteroid injection versus extracorporeal shock wave therapy on inferior trigger points in the quadratus lumborum muscle: a randomized clinical trial. BMC Musculoskelet Disord 2020;21:695.
51. Jeon JH, Jung YJ, Lee JY, et al. The effect of extracorporeal shock wave therapy on myofascial pain syndrome. Ann Rehabil Med 2012;365:665-74.
52. Eroglu PK, Yilmaz Ö, Bodur H, Ates C. A Comparison of the efficacy of dry needling, lidocaine injection, and oral flurbiprofen treatments in patients with myofascial pain syndrome: a double-blind (for injection, groups only), randomized clinical trial. Arch Rheumatol 2013;28:38-46.
53. Raeissadat SA, Rayegani SM, Sadeghi F, Rahimi-Dehgolan S. Comparison of ozone and lidocaine injection efficacy vs dry needling in myofascial pain syndrome patients. J Pain Res. 2018;11:1273-9.
54. Hong CZ. Lidocaine injection versus dry needling to myofascial trigger point. The importance of the local twitch response. Am J Phys Med Rehabil 1994;73:256-63.
55. Ay S, Evcik D, Tur BS. Comparison of injection methods in myofascial pain syndrome: a randomized controlled trial. Clin Rheumatol 2010;29:19-23.
56. Navarro-Santana MJ, Sanchez-Infante J, Fernández-de-las-Peñas C, et al. effectiveness of dry needling for myofascial trigger points associated with neck pain symptoms: an updated systematic review and meta-analysis. J Clin Med 2020;9:3300.
57. Liu L, Huang QM, Liu QG, et al. Effectiveness of dry needling for myofascial trigger points associated with neck and shoulder pain: a systematic review and meta-analysis. Arch Phys Med Rehabil 2015;96:944-55.
58. Al-Moraissi EA, Alradom J, Aladashi O, et al. Needling therapies in the management of myofascial pain of the masticatory muscles: A network meta-analysis of randomised clinical trials. J Oral Rehabil 2020;47:910-22.
59. Ballyns JJ, Turo D, Otto P, et al. Office-based elastographic technique for quantifying mechanical properties of skeletal muscle. J Ultrasound Med 2012;31:1209-19.
60. Kang JJ, Kim J, Park S, et al. Feasibility of Ultrasound-guided trigger point injection in patients with myofascial pain syndrome. Healthcare (Basel) 2019;7(4).
61. So JI, Song DH, Park JH, et al. Accuracy of ultrasound-guided and non-ultrasound-guided botulinum toxin injection into cadaver salivary glands. Ann Rehabil Med 2017;41:51-7.
62. Lamplot JD, Lillegraven O, Brophy RH. Outcomes from conservative treatment of shoulder idiopathic adhesive capsulitis and factors associated with developing contralateral disease. Orthop J Sports Med 2018;6:2325967118785169.
63. Koh SH, Lee SC, Lee WY, et al. Ultrasound-guided intra-articular injection of hyaluronic acid and ketorolac for osteoarthritis of the carpometacarpal joint of the thumb: A retrospective comparative study. Medicine (Baltimore) 2019;98:e15506.
64. Gazi MC, Issy AM, Avila IP, Sakata RK. Comparison of acupuncture to injection for myofascial trigger point pain. Pain Pract 2011;11:132-8.
65. Krishnan SK, Benzon HT, Siddiqui T, Canlas B. Pain on intramuscular injection of bupivacaine, ropivacaine, with and without dexamethasone. Reg Anesth Pain Med 2000;25(615-9.
66. Waterbrook AL, Balcik BJ, Goshinska AJ. Blood glucose levels after local musculoskeletal steroid injections in patients with diabetes mellitus: a clinical review. Sports Health 2017;9:372-4.
67. Noerdlinger MA, Fadale PD. The role of injectable corticosteroids in orthopedics. Orthopedics 2001;24:400-5; quiz 6-7.
68. Yoon SH, Lee HY, Lee HJ, Kwack KS. Optimal dose of intra-articular corticosteroids for adhesive capsulitis: a randomized, triple-blind, placebo-controlled trial. Am J Sports Med 2013;41:1133-9.
69. Prestgaard T, Wormgoor MEA, Haugen S, et al. Ultrasound-guided intra-articular and rotator interval corticosteroid injections in adhesive capsulitis of the shoulder: a double-blind, sham-controlled randomized study. Pain 2015;156:1683-91.
70. Challoumas D, Biddle M, McLean M, Millar NL. Comparison of treatments for frozen shoulder: a systematic review and meta-analysis. JAMA Netw Open 2020;3:e2029581.
71. Alvarez DJ, Rockwell PG. Trigger points: diagnosis and management. Am Fam Physician 2002;65:653-60.

How to Cite

1.
Giannaki A, Rekatsina M, Hassouna M, Cregg R. Efficacy of trigger point injection for non-malignant persistent musculoskeletal pain: a narrative review. Adv Health Res [Internet]. 2025 Jan. 28 [cited 2025 Jan. 30];2. Available from: https://www.ahr-journal.org/site/article/view/30
Copyright (c) 2025 the Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.


Similar Articles

1-10 of 11

You may also start an advanced similarity search for this article.